NVCT
Nuvectis Pharma Inc.
Company Overview
| Mkt Cap | $169.83M | Price | $6.08 |
| Volume | 78.53K | Change | +3.40% |
| P/E Ratio | -8.9 | Open | $5.90 |
| Revenue | -- | Prev Close | $5.88 |
| Net Income | $-19.0M | 52W Range | $4.44 - $11.52 |
| Div Yield | N/A | Target | $18.00 |
| Overall | 25 | Value | 40 |
| Quality | -- | Technical | 10 |
No chart data available
About Nuvectis Pharma Inc.
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Latest News
Maxim Group Reaffirms Their Buy Rating on Nuvectis Pharma (NVCT)
Roth MKM Sticks to Its Buy Rating for Nuvectis Pharma (NVCT)
Nuvectis Pharma’s Phase 1 Study of NXP900: A Potential Game-Changer in Cancer Treatment
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NVCT | $6.08 | +3.4% | 78.53K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |